The Concise Guide to Pharmacology 2019/20:Introduction and Other Protein Targets by  et al.
                                                                    
University of Dundee
The Concise Guide to Pharmacology 2019/20
CGTP Collaborators; Alexander, Stephen P. H.; Kelly, Eamonn; Mathie, Alistair; Peters, John
A.; Veale, Emma L.
Published in:
British Journal of Pharmacology
DOI:
10.1111/bph.14747
Publication date:
2019
Document Version
Publisher's PDF, also known as Version of record
Link to publication in Discovery Research Portal
Citation for published version (APA):
CGTP Collaborators, Alexander, S. P. H., Kelly, E., Mathie, A., Peters, J. A., Veale, E. L., ... Davies, J. A. (2019).
The Concise Guide to Pharmacology 2019/20: Introduction and Other Protein Targets. British Journal of
Pharmacology, 176 (S1), S1-S20. https://doi.org/10.1111/bph.14747
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 07. Dec. 2019

S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: and Other Protein Targets. British Journal of Pharmacology
THE CONCISE GUIDE TO PHARMACOLOGY 2019/20:
Introduction and Other Protein Targets
Stephen PH Alexander1 , Eamonn Kelly2, Alistair Mathie3 , John A Peters4 , Emma L Veale3 , Jane F Armstrong5 ,
Elena Faccenda5 , Simon D Harding5 , Adam J Pawson5 , Joanna L Sharman5 , Christopher Southan5 ,
O Peter Buneman6, John A Cidlowski7 , Arthur Christopoulos8 , Anthony P Davenport9 , Doriano Fabbro10 ,
Michael Spedding11 , Jörg Striessnig12 , Jamie A Davies5 and CGTP Collaborators
1School of Life Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK
2School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, BS8 1TD, UK
3Medway School of Pharmacy, The Universities of Greenwich and Kent at Medway, Anson Building, Central Avenue, Chatham Maritime,
Chatham, Kent, ME4 4TB, UK
4Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK
5Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, EH8 9XD, UK
6Laboratory for Foundations of Computer Science, School of Informatics, University of Edinburgh, Edinburgh, EH8 9LE, UK
7National Institute of Environmental Health Sciences, National Institutes of Health, Department of Health and Human Services, Research Triangle Park,
NC 27709, USA
8Monash Institute of Pharmaceutical Sciences and Department of Pharmacology, Monash University, Parkville, Victoria 3052, Australia
9Clinical Pharmacology Unit, University of Cambridge, Cambridge, CB2 0QQ, UK
10PIQUR Therapeutics, Basel 4057, Switzerland
11Spedding Research Solutions SARL, Le Vésinet 78110, France
12Pharmacology and Toxicology, Institute of Pharmacy, University of Innsbruck, A-6020 Innsbruck, Austria
Abstract
The Concise Guide to PHARMACOLOGY 2019/20 is the fourth in this series of biennial publications. The Concise Guide provides concise overviews of the key properties of nearly 1800 human
drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www.guidetopharmacology.org),
which provides more detailed views of target and ligand properties. Although the Concise Guide represents approximately 400 pages, the material presented is substantially reduced compared
to information and links presented on the website. It provides a permanent, citable, point-in-time record that will survive database updates. The full contents of this section can be found at
http://onlinelibrary.wiley.com/doi/10.1111/bph.14747. In addition to this overview, in which are identiﬁed Other protein targets which fall outside of the subsequent categorisation, there are six
areas of focus: G protein-coupled receptors, ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary
information on the best available pharmacological tools, alongside key references and suggestions for further reading. The landscape format of the Concise Guide is designed to facilitate comparison
of related targets from material contemporary to mid-2019, and supersedes data presented in the 2017/18, 2015/16 and 2013/14 Concise Guides and previous Guides to Receptors and Channels. It is
produced in close conjunction with the International Union of Basic and Clinical Pharmacology Committee on Receptor Nomenclature and Drug Classiﬁcation (NC-IUPHAR), therefore, providing ofﬁcial
IUPHAR classiﬁcation and nomenclature for human drug targets, where appropriate.
Searchable database: http://www.guidetopharmacology.org/index.jsp Other protein targets S1
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Introduction
In order to allow clarity and consistency in pharmacology, there is
a need for a comprehensive organisation and presentation of the
targets of drugs. This is the philosophy of the IUPHAR/BPS Guide
to PHARMACOLOGY presented on the online free access database
(https://www.guidetopharmacology.org/). This database is sup-
ported by the British Pharmacological Society (BPS), the Interna-
tional Union of Basic and Clinical Pharmacology (IUPHAR), the
University of Edinburgh and previously the Wellcome Trust. Data
included in the Guide to PHARMACOLOGY are derived in large
part from interactions with the subcommittees of the Nomencla-
ture Committee of the International Union of Basic and Clinical
Pharmacology (NC-IUPHAR). A major inﬂuence on the develop-
ment of the database was Tony Harmar (1951-2014), who worked
with a passion to establish the curators as a team of highly in-
formed and informative individuals, with a focus on high-quality
data input, ensuring a suitably validated dataset. The Editors of
the Concise Guide have compiled the individual records, in con-
cert with the team of Curators, drawing on the expert knowledge
of these latter subcommittees. The tables allow an indication of
the status of the nomenclature for the group of targets listed,
usually previously published in Pharmacological Reviews. In
the absence of an established subcommittee, advice from several
prominent, independent experts has generally been obtained to
produce an authoritative consensus on nomenclature, which at-
tempts to ﬁt in within the general guidelines from NC-IUPHAR.
This current edition, the Concise Guide to PHARMACOLOGY
2019/20, is the latest snapshot of the database in print form, fol-
lowing on from the Concise Guide to PHARMACOLOGY 2017/18.
It contains data drawn from the online database as a rapid
overview of the major pharmacological targets. Thus, there are
many fewer targets presented in the Concise Guide compared to
the online database. The priority for inclusion in the Concise
Guide is the presence of quantitative pharmacological data for hu-
man proteins. This means that often orphan family members are
not presented in the Concise Guide, although structural informa-
tion is available on the online database. The organisation of the
data is tabular (where appropriate) with a standardised format,
where possible on a single page, intended to aid understanding
of, and comparison within, a particular target group. The Concise
Guide is intended as an initial resource, with links to additional
reviews and resources for greater depth and information. Phar-
macological and structural data focus primarily on human gene
products, wherever possible, with links to HGNC gene nomen-
clature and UniProt IDs. In a few cases, where data from human
proteins are limited, data from other species are indicated. Phar-
macological tools listed are prioritised on the basis of selectivity
and availability. That is, agents (agonists, antagonists, inhibitors,
activators, etc.) are included where they are both available (by
donation or from commercial sources, now or in the near future)
AND the most selective. The Concise Guide is divided into seven
sections, which comprise pharmacological targets of similar struc-
ture/function. These are G protein-coupled receptors, ion chan-
nels (combining previous records of ligand-gated, voltage-gated
and other ion channels), catalytic receptors, nuclear hormone re-
ceptors, enzymes, transporters and other protein targets. We hope
that the Concise Guide will provide for researchers, teachers and
students a state-of-the art source of accurate, curated information
on the background to their work that they will use in the Introduc-
tions to their Research Papers or Reviews, or in supporting their
teaching and studies. We recommend that any citations to in-
formation in the Concise Guide are presented in the following
format: Alexander SPH et al. (2019). The Concise Guide to PHAR-
MACOLOGY 2019/20: Introduction and Other Protein Targets. Br
J Pharmacol 176: S1–S20. In this overview are listed protein tar-
gets of pharmacological interest, which are not G protein-coupled
receptors, ion channels, nuclear hormone receptors, catalytic re-
ceptors, transporters or enzymes.
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S19 Tubulins
– Tumour-associated antigens
– WD repeat-containing proteins
Adiponectin receptors
Other protein targets → Adiponectin receptors
Overview: Adiponectin receptors (provisional nomen-
clature, ENSFM00500000270960) respond to the 30 kDa
complement-related protein hormone adiponectin (also known
as ADIPOQ: adipocyte, C1q and collagen domain-containing pro-
tein; ACRP30, adipose most abundant gene transcript 1; apM-1;
gelatin-binding protein: Q15848) originally cloned from
adipocytes [57]. Although sequence data suggest 7TM domains,
immunological evidence indicates that, contrary to typical 7TM
topology, the carboxyl terminus is extracellular, while the amino
terminus is intracellular [111]. Signalling through these receptors
appears to avoid G proteins; modelling based on the crystal struc-
tures of the adiponectin receptors suggested ceramidase acivity,
which would make these the ﬁrst in a new family of catalytic
receptors [98].
Searchable database: http://www.guidetopharmacology.org/index.jsp Adiponectin receptors S6
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Nomenclature Adipo1 receptor Adipo2 receptor
HGNC, UniProt ADIPOR1, Q96A54 ADIPOR2, Q86V24
Rank order of potency globular adiponectin (ADIPOQ, Q15848) > adiponectin (ADIPOQ, Q15848) globular adiponectin (ADIPOQ, Q15848) = adiponectin (ADIPOQ, Q15848)
Comments: T-Cadherin (CDH13, P55290) has also been suggested to be a receptor for (hexameric) adiponectin [36].
Further reading on Adiponectin receptors
Fisman EZ et al. (2014) Adiponectin: a manifold therapeutic target for metabolic syndrome, dia-
betes, and coronary disease? Cardiovasc Diabetol 13: 103 [PMID:24957699]
Okada-Iwabu M et al. (2018) Structure and function analysis of adiponectin receptors toward de-
velopment of novel antidiabetic agents promoting healthy longevity. Endocr J 65: 971-977
[PMID:30282888]
Ruan H et al. (2016) Adiponectin signaling and function in insulin target tissues. J Mol Cell Biol 8:
101-9 [PMID:26993044]
Wang Y et al. (2017) Cardiovascular Adiponectin Resistance: The Critical Role of Adiponectin Re-
ceptor Modiﬁcation. Trends Endocrinol. Metab. 28: 519-530 [PMID:28473178]
Zhao L et al. (2014) Adiponectin and insulin cross talk: the microvascular connection. Trends Car-
diovasc. Med. 24: 319-24 [PMID:25220977]
Blood coagulation components
Other protein targets → Blood coagulation components
Overview: Coagulation as a process is interpreted as a mechanism for reducing excessive blood loss through the generation of a gel-like clot local to the site of injury. The process involves the activation,
adhesion (see Integrins), degranulation and aggregation of platelets, as well as proteins circulating in the plasma. The coagulation cascade involves multiple proteins being converted to more active forms
from less active precursors, typically through proteolysis (see Proteases). Listed here are the components of the coagulation cascade targetted by agents in current clinical usage.
Nomenclature coagulation factor V coagulation factor VIII serpin family C member 1
HGNC, UniProt F5, P12259 F8, P00451 SERPINC1, P01008
Selective activators – – heparin (pKd 7.8) [29], fondaparinux (pKd 7.5) [72],
dalteparin [35], danaparoid [18, 65], enoxaparin [21],
tinzaparin [22]
Selective inhibitors drotrecogin alfa (Antithrombotic effect thought to
occur via inhibition of factors Va and VIIIa) [39, 40]
drotrecogin alfa (Antithrombotic effect thought to
occur via inhibition of factors Va and VIIIa) [39, 40]
–
Searchable database: http://www.guidetopharmacology.org/index.jsp Blood coagulation components S7
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Further reading on Blood coagulation components
Astermark J. (2015) FVIII inhibitors: pathogenesis and avoidance. Blood 125: 2045-51
[PMID:25712994]
Girolami A et al. (2017) New clotting disorders that cast new light on blood coagulation and may
play a role in clinical practice. J. Thromb. Thrombolysis 44: 71-75 [PMID:28251495]
Rana K et al. (2016) Blood ﬂow and mass transfer regulation of coagulation. Blood Rev. 30: 357-68
[PMID:27133256]
Non-enzymatic BRD containing proteins
Other protein targets → Bromodomain-containing proteins → Non-enzymatic BRD containing proteins
Overview: Bromodomains bind proteins with acetylated lysine residues, such as histones, to regulate gene transcription. Listed herein are examples of bromodomain-containing proteins for which
sufﬁcient pharmacology exists.
Nomenclature bromodomain adjacent
to zinc ﬁnger domain 2A
bromodomain adjacent
to zinc ﬁnger domain 2B
CREB binding protein polybromo 1 SWI/SNF related, matrix
associated, actin dependent
regulator of chromatin, subfamily a,
member 4
HGNC, UniProt BAZ2A, Q9UIF9 BAZ2B, Q9UIF8 CREBBP, Q92793 PBRM1, Q86U86 SMARCA4, P51532
Selective
inhibitors
GSK2801 (pKd 6.6) [85] GSK2801 (Binding) (pKd 6.9) [85] I-CBP112 (pKd 6.8) [84] PFI-3 (Binding) (pKd 7.3) [95] PFI-3 (Binding) (pKd 7.1) [95]
Further reading on Non-enzymatic BRD containing proteins
Fujisawa T et al. (2017) Functions of bromodomain-containing proteins and their roles in home-
ostasis and cancer. Nat. Rev. Mol. Cell Biol. 18: 246-262 [PMID:28053347]
Myrianthopoulos V & Mikros E. (2019) From bench to bedside, via desktop. Recent advances in
the application of cutting-edge in silico tools in the research of drugs targeting bromodomain
modules. Biochem Pharmacol 159: 40-51 [PMID:30414936]
Nicholas DA et al. (2017) BET bromodomain proteins and epigenetic regulation of inﬂamma-
tion: implications for type 2 diabetes and breast cancer. Cell. Mol. Life Sci. 74: 231-243
[PMID:27491296]
Ramadoss M & Mahadevan V. (2018) Targeting the cancer epigenome: synergistic therapy with
bromodomain inhibitors. Drug Discov Today 23: 76-89 [PMID:28943305]
Yang CY et al. (2019) Small-molecule PROTAC degraders of the Bromodomain and Extra Terminal
(BET) proteins - A review. Drug Discov Today Technol 31: 43-51 [PMID:31200858]
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Carrier proteins
Other protein targets → Carrier proteins
Overview: Transthyretin (TTR) is a homo-tetrameric protein
which transports thyroxine in the plasma and cerebrospinal ﬂuid
and retinol (vitamin A) in the plasma. Many disease causing mu-
tations in the protein have been reported, many of which cause
complex dissociation and protein mis-assembly and deposition of
toxic aggregates amyloid ﬁbril formation [73]. These amyloido-
genic mutants are linked to the development of pathological amy-
loidoses, including familial amyloid polyneuropathy (FAP) [6, 16],
familial amyloid cardiomyopathy (FAC) [37], amyloidotic vitre-
ous opacities, carpal tunnel syndrome [63] and others. In old
age, non-mutated TTR can also form pathological amyloid ﬁbrils
[108]. Pharmacological intervention to reduce or prevent TTR dis-
sociation is being pursued as a theapeutic strategy. To date one
small molecule kinetic stabilising molecule (tafamidis) has been
approved for FAP, and is being evaluated in clinical trials for other
TTR amyloidoses.
Nomenclature transthyretin
Common abbreviation TTR
HGNC, UniProt TTR, P02766
Further reading on Carrier proteins
Adams D et al. (2019) Hereditary transthyretin amyloidosis: a model of medical progress for a fatal
disease. Nat Rev Neurol 15: 387-404 [PMID:31209302]
Dellière S et al. (2017) Is transthyretin a good marker of nutritional status? Clin Nutr 36: 364-370
[PMID:27381508]
Galant NJ et al. (2017) Transthyretin amyloidosis: an under-recognized neuropathy and cardiomy-
opathy. Clin. Sci. 131: 395-409 [PMID:28213611]
Yokoyama T & Mizuguchi M. (2018) Inhibition of the Amyloidogenesis of Transthyretin by Natural
Products and Synthetic Compounds. Biol Pharm Bull 41: 979-984 [PMID:29962408]
Ruberg FL et al. (2019) Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review. J
Am Coll Cardiol 73: 2872-2891 [PMID:31171094]
CD molecules
Other protein targets → CD molecules
Overview: Cluster of differentiation refers to an attempt
to catalogue systematically a series of over 300 cell-surface
proteins associated with immunotyping. Many members of
the group have identiﬁed functions as enzymes (for example,
see CD73 ecto-5’-nucleotidase) or receptors (for example, see
CD41 integrin, alpha 2b subunit). Many CDs are targeted for
therapeutic gain using antibodies for the treatment of prolifera-
tive disorders. A full listing of all the Clusters of Differentiation
proteins is not possible in the Guide to PHARMACOLOGY; listed
herein are selected members of the family targeted for therapeutic
gain.
Searchable database: http://www.guidetopharmacology.org/index.jsp CD molecules S9
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Nomenclature CD2 CD3e CD6 CD20 (membrane-spanning 4-domains,
subfamily A, member 1)
CD33
Common abbreviation – – – – SIGLEC-3
HGNC, UniProt CD2, P06729 CD3E, P07766 CD6, P30203 MS4A1, P11836 CD33, P20138
Selective inhibitors alefacept [19, 62] – – – –
Antibodies – catumaxomab (Binding) [50],
muromonab-CD3 (Binding) [28],
otelixizumab (Binding) [11]
– ofatumumab (Binding) (pKd 9.9) [52],
rituximab (Binding) (pKd 8.5) [91],
ibritumomab tiuxetan (Binding),
obinutuzumab (Binding) [4, 76],
tositumomab (Binding)
lintuzumab (Binding) (pKd ∼10) [12],
gemtuzumab ozogamicin (Binding) [9]
Nomenclature CD52 CD80 CD86 cytotoxic T-lymphocyte-
associated
protein 4 (CD152)
programmed cell death
1 (CD279)
CD300a
Common abbreviation – – – CTLA-4 PD-1 –
HGNC, UniProt CD52, P31358 CD80, P33681 CD86, P42081 CTLA4, P16410 PDCD1, Q15116 CD300A,
Q9UGN4
Endogenous ligands – – – – programmed cell death 1 ligand 1
(CD274, Q9NZQ7) (Binding) 
–
Selective inhibitors – abatacept (pKd ∼7.9) [51, 103] abatacept (pKd ∼7.9)
[51, 103], belatacept [44]
– – –
Antibodies alemtuzumab
(Binding) [26, 86]
– – ipilimumab (Binding)
(pKd >9) [30],
tremelimumab (Binding)
(pKd 8.9) [32]
pembrolizumab (Binding) (pKd∼10) [13], nivolumab (Binding)
(pKd 9.1) [31, 42, 43]
–
Comments: The endogenous ligands for human PD-1 are programmed cell death 1 ligand 1 (PD-L1 aka CD274 (CD274, Q9NZQ7)) and programmed cell death 1 ligand 2 (PD-L2; PDCD1LG2). These
ligands are cell surface peptides, normally involved in immune system regulation. Expression of PD-1 by cancer cells induces immune tolerance and evasion of immune system attack. Anti-PD-1
monoclonal antibodies are used to induce immune checkpoint blockade as a therapeutic intervention in cancer, effectively re-establishing immune vigilance. Pembrolizumab was the ﬁrst anti-PD-1
antibody to be approved by the US FDA.
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Further reading on CD molecules
Gabius HJ et al. (2015) The glycobiology of the CD system: a dictionary for translating marker
designations into glycan/lectin structure and function. Trends Biochem. Sci. 40: 360-76
[PMID:25981696]
Vosoughi T et al. (2019) CDmarkers variations in chronic lymphocytic leukemia: New insights into
prognosis. J Cell Physiol. 234: 19420-39 [PMID:31049958]
Methyllysine reader proteins
Other protein targets → Chromatin-interacting transcriptional repressors → Methyllysine reader proteins
Overview: Methyllysine reader proteins bind to methylated proteins, such as histones, allowing regulation of gene expression.
Nomenclature L3MBTL histone methyl-lysine binding protein 3
HGNC, UniProt L3MBTL3, Q96JM7
Selective agonists UNC1215 [38]
Further reading on Methyllysine reader proteins
Daskalaki MG et al. (2018) Histone methylation and acetylation in macrophages as a mechanism
for regulation of inﬂammatory responses. J Cell Physiol. 233: 6495-9507 [PMID:29574768]
Furuya K et al. (2019) Epigenetic interplays between DNA demethylation and histone methylation
for protecting oncogenesis. J Biochem. 165: 297-299 [PMID:30605533]
Levy D. (2019) Lysine methylation signaling of non-histone proteins in the nucleus. Cell Mol Life
Sci 76: 2873-83 [PMID:31123776]
Li J et al. (2019) Understanding histone H3 lysine 36 methylation and its deregulation in disease.
Cell Mol Life Sci in press [PMID:31147750]
Shafabakhsh R et al. (2019) Role of histone modiﬁcation and DNA methylation in signaling path-
ways involved in diabetic retinopathy. J Cell Physiol. 234: 7839-7846 [PMID:30515789]
Fatty acid-binding proteins
Other protein targets → Fatty acid-binding proteins
Overview: Fatty acid-binding proteins are low molecular weight
(100-130 aa) chaperones for long chain fatty acids, fatty acyl CoA
esters, eicosanoids, retinols, retinoic acids and related metabolites
and are usually regarded as being responsible for allowing the
otherwise hydrophobic ligands to be mobile in aqueous media.
These binding proteins may perform functions extracellularly (e.g.
in plasma) or transport these agents; to the nucleus to interact
with nuclear receptors (principally PPARs and retinoic acid recep-
tors [82]) or for interaction with metabolic enzymes. Although se-
quence homology is limited, crystallographic studies suggest con-
served 3D structures across the group of binding proteins.
Searchable database: http://www.guidetopharmacology.org/index.jsp Fatty acid-binding proteins S11
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Nomenclature fatty acid binding protein 1 fatty acid binding protein 2 fatty acid binding protein 3 fatty acid binding protein 4 fatty acid binding protein 5
HGNC, UniProt FABP1, P07148 FABP2, P12104 FABP3, P05413 FABP4, P15090 FABP5, Q01469
Rank order of potency stearic acid, oleic acid >
palmitic acid, linoleic acid >
arachidonic acid,
α-linolenic acid [77]
stearic acid >
palmitic acid,oleic acid >
linoleic acid > arachidonic acid,
α-linolenic acid [77]
stearic acid, oleic acid,
palmitic acid > linoleic acid,
α-linolenic acid,
arachidonic acid [77]
oleic acid, palmitic acid,
stearic acid, linoleic acid >
α-linolenic acid,
arachidonic acid [77]
–
Inhibitors fenoﬁbrate (pKi 7.6) [14] – Rat,
fenoﬁbric acid (pKi 6.5) [14] –
Rat, HTS01037 (pKi 5.1) [33] –
Mouse
– – – compound 13 (pKi 8.7) [97]
Selective inhibitors – – – HM50316 (pKi >9) [53] –
Comments A broader substrate speciﬁcity
than other FABPs, binding two
fatty acids per protein [101].
Crystal structure of the rat
FABP2 [79].
Crystal structure of the human
FABP3 [112].
– Crystal structure of the
human FABP5 [34].
Nomenclature fatty acid binding protein 6 fatty acid binding protein 7 peripheral myelin protein 2 fatty acid binding protein 9 fatty acid binding protein 12
HGNC, UniProt FABP6, P51161 FABP7, O15540 PMP2, P02689 FABP9, Q0Z7S8 FABP12, A6NFH5
Comments Able to transport bile acids
[113].
Crystal structure of the human
FABP7 [7].
In silico modelling suggests that
PMP2/FABP8 can bind both
fatty acids and cholesterol [58].
– –
Nomenclature retinol binding
protein 1
retinol binding
protein 2
retinol binding protein 3 retinol binding protein 4 retinol binding protein 5 retinol binding protein 7
HGNC, UniProt RBP1, P09455 RBP2, P50120 RBP3, P10745 RBP4, P02753 RBP5, P82980 RBP7, Q96R05
Rank order of potency – stearic acid >
palmitic acid,
oleic acid, linoleic acid,
α-linolenic acid,
arachidonic acid [78]
– – – –
Inhibitors – – – A1120 (pIC50 7.8) [106] – –
Searchable database: http://www.guidetopharmacology.org/index.jsp Fatty acid-binding proteins S12
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Nomenclature retinaldehyde binding protein 1 cellular retinoic acid binding protein 1 cellular retinoic acid binding protein 2
HGNC, UniProt RLBP1, P12271 CRABP1, P29762 CRABP2, P29373
Rank order of potency 11-cis-retinal, 11-cis-retinol > 9-cis-retinal,
13-cis-retinal, 13-cis-retinol,
all-trans-retinal, retinol [17]
tretinoin > alitretinoin
stearic acid > palmitic acid, oleic acid, linoleic acid,
α-linolenic acid, arachidonic acid [78]
–
Comments: Although not tested at all FABPs, BMS309403 exhibits high afﬁnity for FABP4 (pIC50 8.8) compared to FABP3 or FABP5 (pIC50 <6.6) [23, 97]. HTS01037 is reported to interfere with FABP4
action [33]. Ibuprofen displays some selectivity for FABP4 (pIC50 5.5) relative to FABP3 (pIC50 3.5) and FABP5 (pIC50 3.8) [56]. Fenoﬁbric acid displays some selectivity for FABP5 (pIC50 5.5) relative to
FABP3 (pIC50 4.5) and FABP4 (pIC50 4.6) [56]. Multiple pseudogenes for the FABPs have been identiﬁed in the human genome.
Further reading on Fatty acid-binding proteins
Gajda AM et al. (2015) Enterocyte fatty acid-binding proteins (FABPs): different functions of liver
and intestinal FABPs in the intestine. Prostaglandins Leukot. Essent. Fatty Acids 93: 9-16
[PMID:25458898]
Glatz JF. (2015) Lipids and lipid binding proteins: a perfect match. Prostaglandins Leukot Essent Fatty
Acids 93: 45-9 [PMID:25154384]
Hotamisligil GS et al. (2015) Metabolic functions of FABPs–mechanisms and therapeutic implica-
tions. Nat Rev Endocrinol 11: 592-605 [PMID:26260145]
Matsumata M et al. (2016) Fatty acid binding proteins and the nervous system: Their impact on
mental conditions. Neurosci. Res. 102: 47-55 [PMID:25205626]
Osumi T et al. (2016) Heart lipid droplets and lipid droplet-binding proteins: Biochemistry, physi-
ology, and pathology. Exp. Cell Res. 340: 198-204 [PMID:26524506]
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Notch receptors
Other protein targets → Notch receptors
Overview: The canonical Notch signalling pathway has four
type I transmembrane Notch receptors (Notch1-4) and ﬁve lig-
ands (DLL1, 2 and 3, and Jagged 1-2). Each member of this highly
conserved receptor family plays a unique role in cell-fate determi-
nation during embryogenesis, differentiation, tissue patterning,
proliferation and cell death [3]. As the Notch ligands are also
membrane bound, cells have to be in close proximity for receptor-
ligand interactions to occur. Cleavage of the intracellular domain
(ICD) of activated Notch receptors by γ-secretase is required for
downstream signalling and Notch-induced transcriptional modu-
lation [20, 66, 83, 109]. This is why γ-secretase inhibitors can be
used to downregulate Notch signalling and explains their anti-
cancer action. One such small molecule is RO4929097 [54],
although development of this compound has been terminated
following an unsuccessful Phase II single agent clinical trial in
metastatic colorectal cancer [94].
Aberrant Notch signalling is implicated in a number of human
cancers [46, 68, 88, 104], with demcizumab and tarextumab iden-
tiﬁed as antibody inhibitors of ligand:receptor binding [74].
Nomenclature notch receptor 1 notch receptor 2 notch receptor 3 notch receptor 4
HGNC, UniProt NOTCH1, P46531 NOTCH2, Q04721 NOTCH3, Q9UM47 NOTCH4, Q99466
Comments Various types of activating and inactivating NOTCH1
mutations have been reported to be associated with human
diseases, for example: aortic valve disease [25, 61],
Adams-Oliver syndrome 5 [92], T-cell acute lymphoblastic
leukemia (T-ALL) [107], chronic lymphocytic leukemia (CLL)
[75] and head and neck squamous cell carcinoma [1, 93].
– – Notch receptor 4 is a potential therapeutic
molecular target for triple-negative breast cancer
[47, 64].
Further reading on Notch receptors
Arumugam TV et al. (2018) Notch signaling and neuronal death in stroke. Prog. Neurobiol. 165-167:
103-116 [PMID:29574014]
Borggrefe T et al. (2016) The Notch intracellular domain integrates signals from Wnt, Hedgehog,
TGFβ/BMP and hypoxia pathways. Biochim. Biophys. Acta 1863: 303-13 [PMID:26592459]
Palmer WH et al. (2015) Ligand-Independent Mechanisms of Notch Activity. Trends Cell Biol. 25:
697-707 [PMID:26437585]
Previs RA et al. (2015) Molecular pathways: translational and therapeutic implications of the Notch
signaling pathway in cancer. Clin. Cancer Res. 21: 955-61 [PMID:25388163]
Takebe N et al. (2015) Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical
update. Nat Rev Clin Oncol 12: 445-64 [PMID:25850553]
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Regulators of G protein Signaling (RGS) proteins
Other protein targets → Regulators of G protein Signaling (RGS) proteins
Overview: Regulators of G protein signalling (RGS) proteins dis-
play a common RGS domain that interacts with the GTP-bound
Gα subunits of heterotrimeric G proteins, enhancing GTP hy-
drolysis by stabilising the transition state [8, 99, 100], leading
to a termination of GPCR signalling. Interactions through pro-
tein:protein interactions of many RGS proteins have been iden-
tiﬁed for targets other than heteromeric G proteins. Sequence
analysis of the 20 RGS proteins suggests four families of RGS: RZ,
R4, R7 and R12 families. Many of these proteins have been iden-
tiﬁed to have effects other than through targetting G proteins.
Included here is RGS4 for which a number of pharmacological
inhibitors have been described.
RZ family
Other protein targets → Regulators of G protein Signaling (RGS) proteins → RZ family
Overview: The RZ family of RGS proteins is less well character-
ized than the other families [69]. It consists of RGS17 (also known
as RGSZ2), RGS19 (also known as GAIP) and RGS20 (with sev-
eral splice variants including RGSZ1 and Ret-RGS). All members
contain an N-terminal cysteine string motif [49] which is a site of
palmitoylation and could serve functions in membrane targeting,
protein stability or aid protein-protein interactions [2, 49]. How-
ever, the function in the case of RZ family RGS proteins is not
yet fully understood. Members of the RZ family of RGS proteins
are the only RGS proteins that have selective GTPase activating-
protein (GAP) activity for Gαz, a function that resulted in the
name of the family [27, 59, 105, 110]. However, the members
of the RZ family are able to also GAP Gαi/o members with varying
selectivity.
Nomenclature regulator of G-protein signaling 17 regulator of G-protein signaling 19 regulator of G-protein signaling 20
Common abbreviation RGS17 RGS19 RGS20
HGNC, UniProt RGS17, Q9UGC6 RGS19, P49795 RGS20, O76081
R4 family
Other protein targets → Regulators of G protein Signaling (RGS) proteins → R4 family
Overview: This is the largest family of RGS proteins.
Searchable database: http://www.guidetopharmacology.org/index.jsp R4 family S15
Full Contents of ConciseGuide: http://onlinelibrary.wiley.com/doi/10.1111/bph.14747/full
S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: and Other Protein Targets. British Journal of Pharmacology (2019) 176, S1–S20Introduction
Nomenclature regulator of G-protein signaling 1 regulator of G-protein signaling 2 regulator of G-protein signaling 3 regulator of G-protein signaling 4
Common abbreviation RGS1 RGS2 RGS3 RGS4
HGNC, UniProt RGS1, Q08116 RGS2, P41220 RGS3, P49796 RGS4, P49798
Selective inhibitors – – – RGS4 inhibitor 11b (pIC50 7.8) [102],
CCG-50014 (pIC50 7.5) [10, 102],
RGS4 inhibitor 13 (pIC50 7.3) [102]
Nomenclature regulator of G-protein
signaling 5
regulator of G-protein
signaling 8
regulator of G-protein
signaling 13
regulator of G-protein
signaling 16
regulator of G-protein
signaling 18
regulator of G-protein
signaling 21
Common abbreviation RGS5 RGS8 RGS13 RGS16 RGS18 RGS21
HGNC, UniProt RGS5, O15539 RGS8, P57771 RGS13, O14921 RGS16, O15492 RGS18, Q9NS28 RGS21, Q2M5E4
R7 family
Other protein targets → Regulators of G protein Signaling (RGS) proteins → R7 family
Overview: This family of RGS proteins shows some selectivity for Gai/o proteins.
Nomenclature regulator of G-protein signaling 6 regulator of G-protein signaling 7 regulator of G-protein signaling 9 regulator of G-protein signaling 11
Common abbreviation RGS6 RGS7 RGS9 RGS11
HGNC, UniProt RGS6, P49758 RGS7, P49802 RGS9, O75916 RGS11, O94810
Searchable database: http://www.guidetopharmacology.org/index.jsp R7 family S16
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R12 family
Other protein targets → Regulators of G protein Signaling (RGS) proteins → R12 family
Overview: The R12 family consists of RGS10, 12 and 14. RGS12
and 14 are large proteins with additional domains that can par-
ticipate in protein-protein interactions and other functions. In
contrast, RGS10 is a small protein consisting of the RGS domain
and small N- and C-termini, similar to members of the R4 family.
However, sequence homology of the RGS10 RGS domain clearly
places it in the R12 family [45]. The Gαi/o-Loco (GoLoco) motif in
RGS12 and 14 has GDI activity (for Guanine nucleotide Dissocia-
tion Inhibitor) towardsGαi1, Gαi2 andGαi3 [41, 87]. Through this
activity RGS12 and RGS14 can inhibit G protein signaling both by
accelerating GTP hydrolysis and by preventing G protein activa-
tion. Splice variants of RGS12 and RGS14 also contain membrane
targeting and protein-protein interaction domains [80, 89, 90].
Nomenclature regulator of G-protein signaling 10 regulator of G-protein signaling 12 regulator of G-protein signaling 14
Common abbreviation RGS10 RGS12 RGS14
HGNC, UniProt RGS10, O43665 RGS12, O14924 RGS14, O43566
Further reading on Regulators of G protein Signaling (RGS) proteins
Alqinyah M et al. (2018) Regulating the regulators: Epigenetic, transcriptional, and post-
translational regulation of RGS proteins. Cell. Signal. 42: 77-87 [PMID:29042285]
Neubig RR et al. (2002) Regulators of G-protein signalling as new central nervous system drug tar-
gets. Nat Rev Drug Discov 1: 187-97 [PMID:12120503]
Sethakorn N et al. (2010) Non-canonical functions of RGS proteins. Cell. Signal. 22: 1274-81
[PMID:20363320]
Sjögren B. (2017) The evolution of regulators of G protein signalling proteins as drug targets - 20
years in the making: IUPHAR Review 21. Br. J. Pharmacol. 174: 427-437 [PMID:28098342]
Sjögren B et al. (2010) Thinking outside of the "RGS box": new approaches to therapeutic targeting
of regulators of G protein signaling. Mol. Pharmacol. 78: 550-7 [PMID:20664002]
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Sigma receptors
Other protein targets → Sigma receptors
Overview: Although termed ’receptors’, the evidence for coupling through conventional signalling pathways is lacking. Initially described as a subtype of opioid receptors, there is only a modest
pharmacological overlap and no structural convergence with the G protein-coupled receptors; the crystal structure of the sigma1 receptor [81] suggests a trimeric structure of a single short transmembrane
domain traversing the endoplasmic reticulum membrane, with the bulk of the protein facing the cytosol. A wide range of compounds, ranging from psychoactive agents to antihistamines, have been
observed to bind to these sites.
Nomenclature sigma non-opioid intracellular receptor 1 σ2
HGNC, UniProt SIGMAR1, Q99720 TMEM97, Q5BJF2
Agonists – 1,3-ditolylguanidine [48] – Guinea pig
Selective agonists PRE-084 [96], (+)-SKF 10.047 –
Antagonists – SM 21 (pIC50 7.2) [55]
Selective antagonists NE-100 (pIC50 8.4) [70], BD-1047 (pIC50 7.4) [60] –
Labelled ligands [3H]pentazocine (Agonist) [3H]-di-o-tolylguanidine (Agonist)
Comments – The sigma2 receptor has been reported to be TMEM97 [5], a 4TM protein partner of NPC1, the Niemann-Pick C1
protein, a 13TM cholesterol-binding protein.
Comments: (-)-pentazocine also shows activity at opioid receptors. The sigma2 receptor has recently been reported to be TMEM97 [5], a 4TM protein partner of NPC1, the Niemann-Pick C1 protein, a
13TM cholesterol-binding protein.
Further reading on Sigma receptors
Chu UB et al. (2016) Biochemical Pharmacology of the Sigma-1 Receptor. Mol. Pharmacol. 89:
142-53 [PMID:26560551]
Gris G et al. (2015) Sigma-1 receptor and inﬂammatory pain. Inﬂamm. Res. 64: 377-81
[PMID:25902777]
Rousseaux CG et al. (2016) Sigma receptors [σRs]: biology in normal and diseased states. J. Recept.
Signal Transduct. Res. 36: 327-388 [PMID:26056947]
Sambo DO et al. (2018) The sigma-1 receptor as a regulator of dopamine neurotransmission: A
potential therapeutic target for methamphetamine addiction. Pharmacol Ther 186: 152-167
[PMID:29360540]
Su TP et al. (2016) The Sigma-1 Receptor as a Pluripotent Modulator in Living Systems. Trends
Pharmacol. Sci. 37: 262-278 [PMID:26869505]
Vavers E et al. (2019) Allosteric Modulators of Sigma-1 Receptor: A Review. Front Pharmacol 10: 223
[PMID:30941035]
Searchable database: http://www.guidetopharmacology.org/index.jsp Sigma receptors S18
Full Contents of ConciseGuide: http://onlinelibrary.wiley.com/doi/10.1111/bph.14747/full
S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: and Other Protein Targets. British Journal of Pharmacology (2019) 176, S1–S20Introduction
Tubulins
Other protein targets → Tubulins
Overview: Tubulins are a family of intracellular proteins most commonly associated with microtubules, part of the cytoskeleton. They are exploited for therapeutic gain in cancer chemotherapy as
targets for agents derived from a variety of natural products: taxanes, colchicine and vinca alkaloids. These are thought to act primarily through β-tubulin, thereby interfering with the normal processes
of tubulin polymer formation and disassembly.
Nomenclature tubulin alpha 1a tubulin alpha 4a tubulin beta class I tubulin beta 3 class III tubulin beta 4B class IVb tubulin beta 8 class VIII
HGNC, UniProt TUBA1A, Q71U36 TUBA4A, P68366 TUBB, P07437 TUBB3, Q13509 TUBB4B, P68371 TUBB8, Q3ZCM7
Inhibitors – – vinblastine (pIC50 9), eribulin (pIC50
8.2) [67], paclitaxel (Mitotic cell cycle
arrest in A431 cells) (pEC50 8.1) [71],
colchicine (pIC50 8) [15], cabazitaxel,
docetaxel, ixabepilone, vincristine
combretastatin A4 (pIC50
8.2) [24]
– –
Further reading on Tubulins
Arnst KE et al. (2019) Current advances of tubulin inhibitors as dual acting small molecules for
cancer therapy. Med Res Rev 39: 1398-1426 [PMID:30746734]
Eshun-Wilson L. (2019) Effects of alpha-tubulin acetylation on microtubule structure and stability.
Proc Natl Acad Sci U S A 116: 10366-10371 [PMID:31072936]
Gadadhar S et al. (2017) The tubulin code at a glance. J. Cell. Sci. 130: 1347-1353 [PMID:28325758]
Magiera MM et al. (2018) Tubulin Posttranslational Modiﬁcations and Emerging Links to Human
Disease. Cell 173: 1323-1327 [PMID:29856952]
Penna LS et al. (2017) Anti-mitotic agents: Are they emerging molecules for cancer treatment?
Pharmacol. Ther. 173: 67-82 [PMID:28174095]
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